Barrington DA, Riedinger C, Haight PJ, Tubbs C, et al. Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis. Gynecol Oncol 2022 Apr 11. pii: S0090-8258(22)00213.
PMID: 35422338